Hossein Maymani1, Kenneth Hess2, Roman Groisberg1, David S Hong3, Aung Naing3, Sarina Piha-Paul3, Filip Janku3, Siqing Fu3, Apostolia M Tsimberidou3, Shubham Pant3, Daniel Karp3, Shuang Liu3, Ming Sun3, John Heymach4, George Simon4, Funda Meric-Bernstam3, Vivek Subbiah5. 1. Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Depart of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: vsubbiah@mdanderson.org.
Abstract
OBJECTIVES: Immunotherapy (IO) has altered the non-small cell lung cancer (NSCLC) therapeutic landscape. However, the majority of patients do not respond to immune-checkpoint blockade, and subsequently either receive further chemotherapy or are referred for clinical trials. Here we examined the outcomes and predictors of response to IO in early phase clinical trials. MATERIALS AND METHODS: We analyzed the records of 74 patients with metastatic NSCLC that were enrolled on phase 1 IO trials within MD Anderson Cancer Center from 1/2010 to 7/2017. RESULTS: The median age was 68, with a median follow-up of 12.3 months. The median lines of prior therapy was three. There were 53 patients who did not receive any IO as a prior line of treatment with a mOS of 8.2 months and mPFS of 3.4 months. There were 21 patients who progressed on a prior IO agent and subsequently went on an IO study with a mOS of 10.5 months and mPFS of 4.3 months, which was similar to patients who did not receive IO OS HR 0.81 (P = .51) and PFS HR 0.85 (P = .59). Royal Marsden Hospital (RMH) prognostic score >1 was predictive of decreased OS HR 3.59 (P = .014) although PFS was not statistically different. MDACC prognostic score was predictive of both OS HR 3.39 (P = .0002) and PFS HR 1.9 (P = .030). ANC/ALC ratio (NLR) of >6 was predictive of decreased survival mOS 3.2 months compared to NLR <6 mOS 11 months; HR 3.0 (P = .0023). CONCLUSIONS: In our heavily pretreated patient population with NSCLC, early phase clinical trials with IO demonstrated similar outcomes to those seen in larger clinical studies that also used immune checkpoint inhibitors. The addition of NLR to RMH and MDACC prognostic scores can identify patients with poor overall outcomes treated with early phase IO studies.
OBJECTIVES: Immunotherapy (IO) has altered the non-small cell lung cancer (NSCLC) therapeutic landscape. However, the majority of patients do not respond to immune-checkpoint blockade, and subsequently either receive further chemotherapy or are referred for clinical trials. Here we examined the outcomes and predictors of response to IO in early phase clinical trials. MATERIALS AND METHODS: We analyzed the records of 74 patients with metastatic NSCLC that were enrolled on phase 1 IO trials within MD Anderson Cancer Center from 1/2010 to 7/2017. RESULTS: The median age was 68, with a median follow-up of 12.3 months. The median lines of prior therapy was three. There were 53 patients who did not receive any IO as a prior line of treatment with a mOS of 8.2 months and mPFS of 3.4 months. There were 21 patients who progressed on a prior IO agent and subsequently went on an IO study with a mOS of 10.5 months and mPFS of 4.3 months, which was similar to patients who did not receive IO OS HR 0.81 (P = .51) and PFS HR 0.85 (P = .59). Royal Marsden Hospital (RMH) prognostic score >1 was predictive of decreased OS HR 3.59 (P = .014) although PFS was not statistically different. MDACC prognostic score was predictive of both OS HR 3.39 (P = .0002) and PFS HR 1.9 (P = .030). ANC/ALC ratio (NLR) of >6 was predictive of decreased survival mOS 3.2 months compared to NLR <6 mOS 11 months; HR 3.0 (P = .0023). CONCLUSIONS: In our heavily pretreated patient population with NSCLC, early phase clinical trials with IO demonstrated similar outcomes to those seen in larger clinical studies that also used immune checkpoint inhibitors. The addition of NLR to RMH and MDACC prognostic scores can identify patients with poor overall outcomes treated with early phase IO studies.
Authors: Alexander Martens; Kilian Wistuba-Hamprecht; Jianda Yuan; Michael A Postow; Phillip Wong; Mariaelena Capone; Gabriele Madonna; Amir Khammari; Bastian Schilling; Antje Sucker; Dirk Schadendorf; Peter Martus; Brigitte Dreno; Paolo A Ascierto; Jedd D Wolchok; Graham Pawelec; Claus Garbe; Benjamin Weide Journal: Clin Cancer Res Date: 2016-05-11 Impact factor: 12.531
Authors: Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara Journal: Lancet Date: 2016-12-13 Impact factor: 79.321
Authors: Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi Journal: Lancet Oncol Date: 2016-10-10 Impact factor: 41.316
Authors: Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245
Authors: P F Ferrucci; P A Ascierto; J Pigozzo; M Del Vecchio; M Maio; G C Antonini Cappellini; M Guidoboni; P Queirolo; P Savoia; M Mandalà; E Simeone; S Valpione; M Altomonte; F Spagnolo; E Cocorocchio; S Gandini; D Giannarelli; C Martinoli Journal: Ann Oncol Date: 2016-01-22 Impact factor: 32.976
Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu Journal: N Engl J Med Date: 2017-09-08 Impact factor: 91.245
Authors: D C Guven; H C Yildirim; E Bilgin; O H Aktepe; H Taban; T K Sahin; I Y Cakir; S Akin; O Dizdar; S Aksoy; S Yalcin; M Erman; S Kilickap Journal: Clin Transl Oncol Date: 2021-02-14 Impact factor: 3.405
Authors: Shang-Jui Wang; Karishma Khullar; Sinae Kim; Nikhil Yegya-Raman; Jyoti Malhotra; Roman Groisberg; Samuel H Crayton; Ann W Silk; John L Nosher; Michael A Gentile; Janice M Mehnert; Salma K Jabbour Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751